- Poster presentation
- Open Access
Anti-epileptic properties of oleamide
© Mikautadze et al; licensee BioMed Central Ltd. 2008
- Published: 23 September 2008
- Public Health
- Neurological Disorder
- Heterogeneous Group
- Folk Medicine
Epilepsy is a heterogeneous group of disorders. It is the most common neurological disorder after the stroke, with a 2–3% life-time risk of being given a diagnosis of epilepsy . Antiepileptogenic drugs that retard or prevent epileptogenesis are not yet available . Extract of the plant Aquilegia vulgaris is widely used in folk medicine as an antiepileptic medicament . We have previously demonstrated that oleamid – sleep inducing lipid and myo-inositol are two compounds acting on γ-aminobuturic acid type A receptors and hence candidates determining the anti-epileptic properties of the plant Aquilegia vulgaris . Further it was shown that myo-inositol reduces the strength of seizures induced either by pentylentetrazol or kainic acid in rats. In the present work we are demonstrating that oleamid also posseses anti-epileptic features and significantly decreases the degrees of convulsions induced by pentylentetrazole in rats.
- Browne TR, Holmes GL: Epilepsy. N Engl J Med. 2001, 344: 1145-1151. 10.1056/NEJM200104123441507.View ArticlePubMedGoogle Scholar
- Loscher W: Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Research. 2002, 50: 105-123. 10.1016/S0920-1211(02)00073-6.View ArticlePubMedGoogle Scholar
- Shreter AI: Medicinal Herbs of Soviet Far East. 1975, Moscow: Medicina, 105-106.Google Scholar
- Solomonia R, Kuchiashvili N, Berulava A, Pkhakadze V, Trapaidze N, Zhvania M, Abesadze I, Kojima H, Dalakishvili N: Purification and identification of components of the Aquilegia vulgaris extract fraction exhibiting anti-epileptic activity. J Biol Phys Chem. 2004, 4: 187-192.Google Scholar
This article is published under license to BioMed Central Ltd.